BioDesign: The Definitive Toolbox for Optimizing Bioconjugate Properties and Expediting Conjugate Synthesis

What is BioDesign™?

The successful development of new antibody drug conjugates (ADCs) requires expert knowledge of antibody engineering, chemical biology, and linker architecture. BioDesign, by Vector Laboratories, provides drug developers ease of access to trusted antibody engineering, crucial bioconjugation products, and unique linker IP. These critical elements in Vector Laboratories' BioDesign toolbox help to maximize your development versatility, overcome resource constraints, enable you to manufacture at scale, and decrease your time-to-market.

Your Proprietary Assets

Targeting and therapeutic biologics



Therapeutic and diagnostic payloads



BioDesign Toolbox for Your Therapeutics, Diagnostics, and Drug Delivery Systems

Custom antibody engineering and off-the-shelf biologics

Reliable outsourcing solutions for antibody sequencing, engineering, and expression, and true consultative support for the development of antibody candidates. Antibody engineering capabilities include multispecifics, fragments, scFv conversions, humanization, Fc silencing, and half-life optimization.



Research-grade biosimilars, isotype controls, and immunotherapy research antibodies are available in off-the-shelf formats and have been enhanced for improved performance *in vivo*.

Ready-to-use linkers and custom synthesis services

Linker architectures for increasing hydrophilicity, increasing hydrodynamic volume, controlling proximities, shielding undesirable attributes of the payload and/or biologic, adding property modifying functionalities, and carrying multiple payloads.



Reactive groups (RG) for stochastic conjugation, site-specific conjugation, biorthogonal conjugation, and enzymatic ligation



Conjugates with Optimized Physiochemical, Pharmacodynamic, and Pharmacokinetic Properties

Facile chemical generation and optimization of non-IgG-like bispecifics



Optimize binding affinity and immune agonism with bicyclic TCE and NKEs



Increase hydrodynamic radius and reduce kidney uptake of diabody conjugates



Improve intracellular delivery and target knockdown with siRNA



Reduce hydrophobicity and non-specific POI degradation with PROTAC-antibody conjugates



Minimize aggregation and improve activity with checkpoint Inhibitors



Optimize yield and reduce aggregation with STING agonists